In this double-blind trial , we randomly assigned 8442 patients with class II , III , or IV heart failure and an ejection fraction of 40 % or less to receive either LCZ696 ( at a dose of 200 mg twice daily ) or enalapril ( at a dose of 10 mg twice daily ) , in addition to recommended therapy .